IL208064A - Intrauterine system - Google Patents
Intrauterine systemInfo
- Publication number
- IL208064A IL208064A IL208064A IL20806410A IL208064A IL 208064 A IL208064 A IL 208064A IL 208064 A IL208064 A IL 208064A IL 20806410 A IL20806410 A IL 20806410A IL 208064 A IL208064 A IL 208064A
- Authority
- IL
- Israel
- Prior art keywords
- frame
- reservoir
- uterine
- intrauterine
- core
- Prior art date
Links
- -1 polyethylene Polymers 0.000 claims description 72
- 229920000642 polymer Polymers 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 47
- 239000012528 membrane Substances 0.000 claims description 42
- 238000003780 insertion Methods 0.000 claims description 36
- 230000037431 insertion Effects 0.000 claims description 36
- 239000013543 active substance Substances 0.000 claims description 32
- 229910052751 metal Inorganic materials 0.000 claims description 30
- 239000002184 metal Substances 0.000 claims description 30
- 210000004291 uterus Anatomy 0.000 claims description 29
- 229920001971 elastomer Polymers 0.000 claims description 22
- 239000000806 elastomer Substances 0.000 claims description 21
- 230000009975 flexible effect Effects 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000004433 Thermoplastic polyurethane Substances 0.000 claims description 13
- 238000001746 injection moulding Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 229920002803 thermoplastic polyurethane Polymers 0.000 claims description 12
- 230000008093 supporting effect Effects 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 7
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 7
- 229920002379 silicone rubber Polymers 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 4
- 230000014759 maintenance of location Effects 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000013329 compounding Methods 0.000 claims description 3
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 3
- 230000007774 longterm Effects 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 2
- 229920005570 flexible polymer Polymers 0.000 claims 1
- 239000011162 core material Substances 0.000 description 65
- 239000000463 material Substances 0.000 description 39
- 210000004379 membrane Anatomy 0.000 description 39
- 239000000126 substance Substances 0.000 description 26
- 229920001577 copolymer Polymers 0.000 description 17
- 238000013461 design Methods 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 208000002193 Pain Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 210000003679 cervix uteri Anatomy 0.000 description 11
- 230000002254 contraceptive effect Effects 0.000 description 11
- 238000001125 extrusion Methods 0.000 description 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 10
- 239000003433 contraceptive agent Substances 0.000 description 10
- QYLFHLNFIHBCPR-UHFFFAOYSA-N 1-ethynylcyclohexan-1-ol Chemical compound C#CC1(O)CCCCC1 QYLFHLNFIHBCPR-UHFFFAOYSA-N 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 239000004971 Cross linker Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 6
- 239000000376 reactant Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Natural products C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 5
- 210000003484 anatomy Anatomy 0.000 description 5
- 230000002357 endometrial effect Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 229910052697 platinum Inorganic materials 0.000 description 5
- 229920001169 thermoplastic Polymers 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 229960004400 levonorgestrel Drugs 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 208000007106 menorrhagia Diseases 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 4
- 229920000468 styrene butadiene styrene block copolymer Polymers 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 239000004416 thermosoftening plastic Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 239000004952 Polyamide Substances 0.000 description 3
- 229920002614 Polyether block amide Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BFMKFCLXZSUVPI-UHFFFAOYSA-N ethyl but-3-enoate Chemical compound CCOC(=O)CC=C BFMKFCLXZSUVPI-UHFFFAOYSA-N 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 238000009533 lab test Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 229920002647 polyamide Polymers 0.000 description 3
- 229920000570 polyether Polymers 0.000 description 3
- 229920003245 polyoctenamer Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 229940058401 polytetrafluoroethylene Drugs 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 235000011437 Amygdalus communis Nutrition 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- YNVGQYHLRCDXFQ-XGXHKTLJSA-N Lynestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 YNVGQYHLRCDXFQ-XGXHKTLJSA-N 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 241000220304 Prunus dulcis Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241001465385 Solandra grandiflora Species 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 206010061401 Uterine injury Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000020224 almond Nutrition 0.000 description 2
- 230000000842 anti-protozoal effect Effects 0.000 description 2
- 239000003904 antiprotozoal agent Substances 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- FACXGONDLDSNOE-UHFFFAOYSA-N buta-1,3-diene;styrene Chemical compound C=CC=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 FACXGONDLDSNOE-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000004696 endometrium Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940052303 ethers for general anesthesia Drugs 0.000 description 2
- GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 description 2
- 230000005294 ferromagnetic effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 206010022694 intestinal perforation Diseases 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000005304 joining Methods 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920006030 multiblock copolymer Polymers 0.000 description 2
- 210000000754 myometrium Anatomy 0.000 description 2
- 229940053934 norethindrone Drugs 0.000 description 2
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 2
- 229920000582 polyisocyanurate Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 239000000583 progesterone congener Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 229910052715 tantalum Inorganic materials 0.000 description 2
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229960000834 vinyl ether Drugs 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- BOOBDAVNHSOIDB-UHFFFAOYSA-N (2,3-dichlorobenzoyl) 2,3-dichlorobenzenecarboperoxoate Chemical compound ClC1=CC=CC(C(=O)OOC(=O)C=2C(=C(Cl)C=CC=2)Cl)=C1Cl BOOBDAVNHSOIDB-UHFFFAOYSA-N 0.000 description 1
- QUXXMDBEXONHEI-ZIJGYIGMSA-N (8S,9S,10R,13S,14S,17S)-17-acetyl-16-(hydroxymethyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(CO)[C@H](C(=O)C)[C@@]1(C)CC2 QUXXMDBEXONHEI-ZIJGYIGMSA-N 0.000 description 1
- KLFRPGNCEJNEKU-FDGPNNRMSA-L (z)-4-oxopent-2-en-2-olate;platinum(2+) Chemical compound [Pt+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O KLFRPGNCEJNEKU-FDGPNNRMSA-L 0.000 description 1
- LOVNYFVWYTXDRE-WMSSUOLPSA-N 16-Hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(O)[C@H](C(=O)C)[C@@]1(C)CC2 LOVNYFVWYTXDRE-WMSSUOLPSA-N 0.000 description 1
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- ZMLDTNLDYRJTAZ-GDLCRWSOSA-N 3b-Hydroxydesogestrel Chemical compound O[C@H]1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 ZMLDTNLDYRJTAZ-GDLCRWSOSA-N 0.000 description 1
- DSUFPYCILZXJFF-UHFFFAOYSA-N 4-[[4-[[4-(pentoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamoyloxy]butyl n-[4-[[4-(butoxycarbonylamino)cyclohexyl]methyl]cyclohexyl]carbamate Chemical compound C1CC(NC(=O)OCCCCC)CCC1CC1CCC(NC(=O)OCCCCOC(=O)NC2CCC(CC3CCC(CC3)NC(=O)OCCCC)CC2)CC1 DSUFPYCILZXJFF-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 1
- 206010000228 Abortion infected Diseases 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229910001316 Ag alloy Inorganic materials 0.000 description 1
- ATXHVCQZZJYMCF-XUDSTZEESA-N Allylestrenol Chemical compound C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)CC=C)[C@@H]4[C@@H]3CCC2=C1 ATXHVCQZZJYMCF-XUDSTZEESA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000036829 Device dislocation Diseases 0.000 description 1
- LVHOURKCKUYIGK-RGUJTQARSA-N Dimethisterone Chemical compound C1([C@@H](C)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C#CC)(O)[C@@]2(C)CC1 LVHOURKCKUYIGK-RGUJTQARSA-N 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 241000271915 Hydrophis Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 208000008067 Intrauterine Device Expulsion Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 229920000299 Nylon 12 Polymers 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000005062 Polybutadiene Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920002396 Polyurea Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 208000002359 Septic Abortion Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 206010056738 Uterine cervical laceration Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046810 Uterine perforation Diseases 0.000 description 1
- 206010046823 Uterine spasm Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229960002692 allylestrenol Drugs 0.000 description 1
- XYLMUPLGERFSHI-UHFFFAOYSA-N alpha-Methylstyrene Chemical compound CC(=C)C1=CC=CC=C1 XYLMUPLGERFSHI-UHFFFAOYSA-N 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 230000000708 anti-progestin effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003418 antiprogestin Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 239000003060 catalysis inhibitor Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- VUHJZBBCZGVNDZ-TTYLFXKOSA-N chlormadinone Chemical compound C1=C(Cl)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 VUHJZBBCZGVNDZ-TTYLFXKOSA-N 0.000 description 1
- 229960003996 chlormadinone Drugs 0.000 description 1
- HLRNWZLPRFTCIO-IPZCTEOASA-N chloroethene;diethyl (e)-but-2-enedioate Chemical compound ClC=C.CCOC(=O)\C=C\C(=O)OCC HLRNWZLPRFTCIO-IPZCTEOASA-N 0.000 description 1
- 229920006212 co-poly(ether-esters) Polymers 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000002844 continuous effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000003984 copper intrauterine device Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 description 1
- 229960003309 dienogest Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 229950006690 dimethisterone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 201000003511 ectopic pregnancy Diseases 0.000 description 1
- CKFBRGLGTWAVLG-GOMYTPFNSA-N elcometrine Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 CKFBRGLGTWAVLG-GOMYTPFNSA-N 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 description 1
- 229950009589 estetrol Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- GRXPVLPQNMUNNX-MHJRRCNVSA-N estrane Chemical compound C1CC2CCCC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CCC[C@@]1(C)CC2 GRXPVLPQNMUNNX-MHJRRCNVSA-N 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960002568 ethinylestradiol Drugs 0.000 description 1
- 229920006242 ethylene acrylic acid copolymer Polymers 0.000 description 1
- 229920005648 ethylene methacrylic acid copolymer Polymers 0.000 description 1
- 229960002941 etonogestrel Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 229940121370 gene therapy substance Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000006459 hydrosilylation reaction Methods 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008206 lipophilic material Substances 0.000 description 1
- 229960001910 lynestrenol Drugs 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- FRQMUZJSZHZSGN-HBNHAYAOSA-N medroxyprogesterone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FRQMUZJSZHZSGN-HBNHAYAOSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- JBVNBBXAMBZTMQ-CEGNMAFCSA-N megestrol Chemical compound C1=CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 JBVNBBXAMBZTMQ-CEGNMAFCSA-N 0.000 description 1
- OKHAOBQKCCIRLO-IBVJIVQJSA-N melengestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@@](C(=O)C)(O)[C@@]1(C)CC2 OKHAOBQKCCIRLO-IBVJIVQJSA-N 0.000 description 1
- 229960004805 melengestrol Drugs 0.000 description 1
- IMSSROKUHAOUJS-MJCUULBUSA-N mestranol Chemical compound C1C[C@]2(C)[C@@](C#C)(O)CC[C@H]2[C@@H]2CCC3=CC(OC)=CC=C3[C@H]21 IMSSROKUHAOUJS-MJCUULBUSA-N 0.000 description 1
- 229960001390 mestranol Drugs 0.000 description 1
- 239000013528 metallic particle Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 1
- 229960004911 nomegestrol Drugs 0.000 description 1
- 239000003402 opiate agonist Substances 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229920000771 poly (alkylcyanoacrylate) Polymers 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920001490 poly(butyl methacrylate) polymer Polymers 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920001849 poly(hydroxybutyrate-co-valerate) Polymers 0.000 description 1
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 229920003224 poly(trimethylene oxide) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002857 polybutadiene Polymers 0.000 description 1
- 229920001748 polybutylene Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229960004183 quingestanol Drugs 0.000 description 1
- PCJFRMOEZQQSAX-AIOSZGMZSA-N quingestanol Chemical compound C([C@@H]1[C@@H]([C@H]2CC3)CC[C@]4([C@H]1CC[C@@]4(O)C#C)C)C=C2C=C3OC1CCCC1 PCJFRMOEZQQSAX-AIOSZGMZSA-N 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 229920005604 random copolymer Polymers 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 238000001175 rotational moulding Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- PYVFWTPEBMRKSR-UHFFFAOYSA-N tanaproget Chemical compound CN1C(C#N)=CC=C1C1=CC=C(NC(=S)OC2(C)C)C2=C1 PYVFWTPEBMRKSR-UHFFFAOYSA-N 0.000 description 1
- 229950001471 tanaproget Drugs 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 description 1
- 229950008546 trimegestone Drugs 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/142—Wirelike structures, e.g. loops, rings, spirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/39—Markers, e.g. radio-opaque or breast lesions markers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
- A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
- A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
- A61F6/18—Inserters or removers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B34/00—Computer-aided surgery; Manipulators or robots specially adapted for use in surgery
- A61B34/20—Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
- A61B2034/2046—Tracking techniques
- A61B2034/2065—Tracking using image or pattern recognition
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Robotics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Pathology (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Surgical Instruments (AREA)
- Electrotherapy Devices (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20085277A FI20085277A0 (fi) | 2008-04-02 | 2008-04-02 | Kohdunsisäinen järjestelmä |
| PCT/FI2009/050244 WO2009122016A1 (en) | 2008-04-02 | 2009-04-01 | An intrauterine system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL208064A0 IL208064A0 (en) | 2010-12-30 |
| IL208064A true IL208064A (en) | 2013-03-24 |
Family
ID=39385905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL208064A IL208064A (en) | 2008-04-02 | 2010-09-07 | Intrauterine system |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US20110056501A1 (enExample) |
| EP (1) | EP2271293B1 (enExample) |
| JP (2) | JP5591790B2 (enExample) |
| KR (1) | KR101592615B1 (enExample) |
| CN (1) | CN101983041A (enExample) |
| AR (1) | AR071170A1 (enExample) |
| AU (1) | AU2009232105B2 (enExample) |
| BR (1) | BRPI0906317B8 (enExample) |
| CA (1) | CA2719957C (enExample) |
| CL (1) | CL2009000756A1 (enExample) |
| CO (1) | CO6311060A2 (enExample) |
| CR (1) | CR11739A (enExample) |
| CU (1) | CU20100193A7 (enExample) |
| EA (1) | EA021575B1 (enExample) |
| EC (1) | ECSP10010495A (enExample) |
| FI (1) | FI20085277A0 (enExample) |
| GT (1) | GT201000278A (enExample) |
| IL (1) | IL208064A (enExample) |
| MX (1) | MX2010010591A (enExample) |
| MY (1) | MY155344A (enExample) |
| NZ (1) | NZ587600A (enExample) |
| PE (1) | PE20100283A1 (enExample) |
| SG (1) | SG189736A1 (enExample) |
| SV (1) | SV2010003678A (enExample) |
| TW (1) | TWI505820B (enExample) |
| UA (1) | UA100410C2 (enExample) |
| UY (1) | UY31746A (enExample) |
| WO (1) | WO2009122016A1 (enExample) |
| ZA (1) | ZA201006144B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) * | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| MX2009000053A (es) * | 2006-07-12 | 2009-02-23 | Controlled Therapeutics Sct | Polimero para el suministro de medicamentos con sal clorhidrato de clindamicina. |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| FI20080523A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
| FI20080524A0 (fi) | 2008-09-17 | 2008-09-17 | Bayer Schering Pharma Oy | Insertteri |
| RU2494706C2 (ru) | 2008-09-17 | 2013-10-10 | Байер Ой | Устройство для введения |
| FI123146B (fi) * | 2009-10-01 | 2012-11-30 | Bayer Schering Pharma Oy | Kohdunsisäinen järjestelmä |
| CN102525722A (zh) * | 2010-12-30 | 2012-07-04 | 辽宁爱母医疗科技有限公司 | 具有记忆效应的智能型复方孕二烯酮阴道环制剂及其应用 |
| US20150320766A1 (en) * | 2012-12-14 | 2015-11-12 | Laboratoire Hra-Pharma | Copper intrauterine device |
| TN2016000134A1 (en) * | 2013-10-18 | 2017-10-06 | Bayer Oy | Intrauterine delivery system. |
| KR20170021929A (ko) * | 2014-06-28 | 2017-03-02 | 라보라토리오스 안드로마코 에스.에이. | 조산 예방에 유용한 지속적, 서방성, 및 연속 방출의 프로게스테론 함유 원형 결찰 페서리 |
| ES3032993T3 (en) * | 2014-09-09 | 2025-07-29 | Qpharma Ab | An overmouldable substrate and uses thereof |
| US11026832B2 (en) * | 2015-05-30 | 2021-06-08 | Pregna International Limited | Intrauterine device with a restricted upward movement of a string |
| AU2016291095B2 (en) | 2015-07-09 | 2021-04-29 | ULTl PHARMACEUTICALS LIMITED | A drug delivery device |
| JP7033342B2 (ja) * | 2018-04-19 | 2022-03-10 | 易浦潤（上海）生物技術有限公司 | 子宮腔内に用いられ内膜ベース層を再活性化させる機能を具備する弾性膜及びその製造方法 |
| CN109044507A (zh) * | 2018-09-27 | 2018-12-21 | 武汉恒鑫康得科技有限公司 | 自成型宫腔球囊 |
| US11524146B2 (en) | 2019-03-15 | 2022-12-13 | Covidien Lp | Methods and devices for transcervical treatment of endometrial cancer and hyperplasia |
| US11844857B2 (en) | 2019-06-27 | 2023-12-19 | Covidien Lp | Treating gynecological malignancies with deployable implants |
| IL292825B1 (en) | 2019-11-12 | 2026-06-01 | Poly Med Inc | Medical devices for preventing pregnancy |
| TW202142200A (zh) * | 2020-01-24 | 2021-11-16 | 芬蘭商拜耳股份有限公司 | 用於具有鎖定部件之子宮內系統的插入物 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3431906A (en) * | 1966-04-22 | 1969-03-11 | Univ Johns Hopkins | Contraceptive device |
| US3467087A (en) * | 1966-09-23 | 1969-09-16 | Paul Erik Lebech | Intrauterine device |
| CH477873A (fr) * | 1967-07-14 | 1969-09-15 | Apamed Anst | Dispositif intra-utérin de contraception |
| US3834378A (en) * | 1970-11-12 | 1974-09-10 | Robins Co Inc A H | Intrauterine device |
| BE791737A (fr) * | 1971-06-23 | 1973-03-16 | Robins Co Inc A H | Dispositif a bords festonnes pour insertion |
| US3889666A (en) * | 1971-10-07 | 1975-06-17 | Robins Co Inc A H | Method of preparation for/and insertion of IUD prepackaged in a tubular inserter |
| US3938515A (en) * | 1971-12-20 | 1976-02-17 | Alza Corporation | Novel drug permeable wall |
| US4188951A (en) * | 1972-08-17 | 1980-02-19 | Alza Corporation | Intrauterine system embracing selected copolymeric membranes for administering beneficial agent |
| US3913573A (en) * | 1972-10-02 | 1975-10-21 | Morton Gutnick | Intrauterine contraceptive devices with plural parallel leg segments |
| FR2250520B1 (enExample) * | 1973-11-09 | 1977-04-15 | Cournut Rene | |
| ES232273Y (es) * | 1977-11-23 | 1978-08-01 | Dispositivo intrauterino con agente anticonceptivo para la mujer. | |
| FI59719C (fi) * | 1978-06-29 | 1987-05-05 | Medholding Oy | Foerfarande foer framstaellning av interuterina preventivmedel. |
| FR2477868A1 (fr) * | 1980-03-17 | 1981-09-18 | Arts Tech Nles | Dispositif contraceptif destine a etre place dans la cavite uterine |
| FR2541891B1 (fr) * | 1983-03-01 | 1986-06-27 | Cl Chimiotherapie De Lab | Dispositif contraceptif intra-uterin |
| NL8601570A (nl) * | 1986-06-17 | 1988-01-18 | Futura Nova Bv | Intra-uterine anticonceptieinrichting. |
| US4841991A (en) * | 1987-09-03 | 1989-06-27 | Nauchno-Proizvodstvennoe Obiedinenie "Medinstrument" | Intrauterine contraceptive device |
| GB8819305D0 (en) * | 1988-08-12 | 1988-09-14 | Gardosi J O | Threadless intrauterine contraceptive device & forceps for removal |
| CN2170749Y (zh) * | 1993-09-23 | 1994-07-06 | 刘锋 | 一次性药铜复合型宫形宫内节育器 |
| AU4894196A (en) * | 1995-03-09 | 1996-10-08 | Jury Vasilievich Borodin | Intrauterine contraceptive device |
| JPH10279499A (ja) * | 1997-04-04 | 1998-10-20 | Takeda Chem Ind Ltd | 子宮粘膜適用製剤 |
| US20060089658A1 (en) * | 2004-10-21 | 2006-04-27 | Harrington Douglas C | Method and apparatus for treating abnormal uterine bleeding |
| FR2881046A1 (fr) * | 2005-01-25 | 2006-07-28 | 7 Med Ind Sa | Procede de fabrication d'un reservoir contenant une substance active diffusant a travers le reservoir et installation pour sa mise en oeuvre |
| FI123188B (fi) * | 2005-04-05 | 2012-12-14 | Bayer Oy | Ultraäänellä havaittavissa oleva kohdunsisäinen järjestelmä |
| US7862552B2 (en) * | 2005-05-09 | 2011-01-04 | Boston Scientific Scimed, Inc. | Medical devices for treating urological and uterine conditions |
| CN1701775A (zh) * | 2005-06-15 | 2005-11-30 | 林志春 | 柔性节育器及其送取装置 |
| FI123146B (fi) * | 2009-10-01 | 2012-11-30 | Bayer Schering Pharma Oy | Kohdunsisäinen järjestelmä |
-
2008
- 2008-04-02 FI FI20085277A patent/FI20085277A0/fi not_active Application Discontinuation
-
2009
- 2009-03-13 TW TW098108165A patent/TWI505820B/zh not_active IP Right Cessation
- 2009-03-27 CL CL2009000756A patent/CL2009000756A1/es unknown
- 2009-03-31 AR ARP090101137A patent/AR071170A1/es active IP Right Grant
- 2009-03-31 UY UY0001031746A patent/UY31746A/es not_active Application Discontinuation
- 2009-03-31 PE PE2009000474A patent/PE20100283A1/es active IP Right Grant
- 2009-04-01 US US12/935,953 patent/US20110056501A1/en not_active Abandoned
- 2009-04-01 NZ NZ587600A patent/NZ587600A/xx not_active IP Right Cessation
- 2009-04-01 SG SG2013024773A patent/SG189736A1/en unknown
- 2009-04-01 KR KR1020107024683A patent/KR101592615B1/ko not_active Expired - Fee Related
- 2009-04-01 CN CN2009801121960A patent/CN101983041A/zh active Pending
- 2009-04-01 MX MX2010010591A patent/MX2010010591A/es active IP Right Grant
- 2009-04-01 JP JP2011502405A patent/JP5591790B2/ja not_active Expired - Fee Related
- 2009-04-01 WO PCT/FI2009/050244 patent/WO2009122016A1/en not_active Ceased
- 2009-04-01 EP EP09727947.5A patent/EP2271293B1/en active Active
- 2009-04-01 EA EA201071151A patent/EA021575B1/ru not_active IP Right Cessation
- 2009-04-01 BR BRPI0906317A patent/BRPI0906317B8/pt not_active IP Right Cessation
- 2009-04-01 CA CA2719957A patent/CA2719957C/en not_active Expired - Fee Related
- 2009-04-01 MY MYPI2010004200A patent/MY155344A/en unknown
- 2009-04-01 AU AU2009232105A patent/AU2009232105B2/en not_active Ceased
- 2009-04-01 UA UAA201012952A patent/UA100410C2/ru unknown
-
2010
- 2010-08-27 ZA ZA2010/06144A patent/ZA201006144B/en unknown
- 2010-09-07 IL IL208064A patent/IL208064A/en active IP Right Grant
- 2010-09-21 EC EC2010010495A patent/ECSP10010495A/es unknown
- 2010-09-27 SV SV2010003678A patent/SV2010003678A/es unknown
- 2010-09-30 GT GT201000278A patent/GT201000278A/es unknown
- 2010-10-01 CU CU20100193A patent/CU20100193A7/es unknown
- 2010-10-15 CR CR11739A patent/CR11739A/es unknown
- 2010-11-02 CO CO10135578A patent/CO6311060A2/es active IP Right Grant
-
2013
- 2013-10-24 US US14/062,881 patent/US20150051481A1/en not_active Abandoned
-
2014
- 2014-04-11 JP JP2014081516A patent/JP2014204989A/ja active Pending
-
2017
- 2017-08-01 US US15/665,741 patent/US20170367876A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2271293B1 (en) | An intrauterine system | |
| EP2482768B1 (en) | An intrauterine system | |
| CN102355872B (zh) | 新型宫内节育器 | |
| KR20220098182A (ko) | 신체 내부용 의료 디바이스 | |
| HK1150957A (en) | An intrauterine system | |
| HK1170145B (zh) | 子宫内系统 | |
| TW202142199A (zh) | 具有護套之子宮內系統 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |